Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2018.12.12
第四届监事会第十四次聚会决议通告
2018.12.12
关于召开2018年第五次暂时股东大会的通知通告
2018.12.12
第三期员工持股妄想(草案)摘要
2018.11.27
关于子公司新药获得快速通道审评的提醒性通告
2018.10.30
第四届董事会第十八次聚会决议通告
2018.10.30
第四届监事会第十三次聚会决议通告
2018.10.30
关于会计政策变换的通告
2018.10.30
关于统一控制下企业合并追溯调解财务数据的通告
2018.10.30
关于子公司新药获得允许进入临床II期试验的提醒性通告
2018.10.29
“16Z6尊龙”2018年付息通告
第一页
上一页
48
49
50
51
52
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】